The customer contacted the siemens customer care center regarding a positive dimension sars-cov-2 total antibody (cv2t) patient sample result obtained on a dimension exl 200.Siemens healthcare diagnostics headquarters support center (hsc) concluded the evaluation of the event.Hsc has reviewed the instrument data.No product non-conformance was identified.The questioned positive cv2t patient sample result was sent to an alternate laboratory and resulted negative on the alternate methodology.The patient was reported to have had two doses of a covid-19 vaccine.The dimension cv2t assay uses the antigen s1 rbd (spike receptor binding domain) which is the same antigen used in the vaccine.The alternate methodology covid assay was reportedly using a nucleocapsid antigen which is not used in currently available vaccines.When a patient receives the vaccine and produces an immune response to the vaccine, that immune response will produce antibodies to the s1 rbd antigen but not to the nucleocapsid antigens.The dimension cv2t assay performed according to specification and produced a correct result with this patient sample.The dimension cv2t result is not discordant but reflects that the patient received a covid-19 vaccine.The limitations section of the dimension sars-cov-2 (cv2t) flex reagent cartridge instructions for use states: "this assay should not be used to diagnose or exclude acute infection.Results are not intended to be used as the sole basis for patient management decisions.Test results should be interpreted in conjunction with clinical observations, patient history, epidemiological information, and other laboratory findings." although there is no potential for serious injury in this case, an mdr will be reported to the fda as a requirement of the emergency use authorization (eua).
|